Breaking News
This Will Piss You Off!
This GENIUS Trellis Trick Grows MORE Cucumbers with LESS Effort
MOLD FREE COFFEE?! From Bean to Brew: Unlocking Pure Coffee Bliss with Lore Coffee Roasters
Boots on the Ground...15 viewers share the good and bad of the US economy.
Top Tech News
Hydrogen Gas Blend Will Reduce Power Plant's Emissions by 75% - as it Helps Power 6 States
The Rise & Fall of Dome Houses: Buckminster Fuller's Geodesic Domes & Dymaxion
New AI data centers will use the same electricity as 2 million homes
Is All of This Self-Monitoring Making Us Paranoid?
Cavorite X7 makes history with first fan-in-wing transition flight
Laser-powered fusion experiment more than doubles its power output
Watch: Jetson's One Aircraft Just Competed in the First eVTOL Race
Cab-less truck glider leaps autonomously between road and rail
Can Tesla DOJO Chips Pass Nvidia GPUs?
Iron-fortified lumber could be a greener alternative to steel beams
At $2.1 million, newly approved Novartis gene therapy will be world's most expensive drug
Known as Zolgensma, the gene therapy treats children under 2 years of age with spinal muscular atrophy, an inherited neuromuscular disease that causes progressive loss of muscle function. The most severe form of SMA causes infants to die or rely on permanent breathing support by the age of 2. The disease is caused by a defect in a gene that makes SMN, a protein necessary for the survival of motor neurons. Zolgensma uses a re-engineered virus to deliver a functional copy of the defective gene so that SMN protein can be produced.
Novartis is pricing Zolgensma at $2.125 million, or an annualized cost of $425,000 per year for five years, the company said.
Launching Zolgensma will be a big test for Novartis and CEO Vas Narasimhan, now two years on the job. Shareholders expect the gene therapy to deliver blockbuster sales to justify the $8.7 billion that Novartis spent to acquire it last year.